Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Appendix B: Panel Roster and Financial Disclosures

Section Review Group

Last Updated: January 1, 2020; Last Reviewed: January 1, 2020

Section Review Group
Member Financial Disclosure
Company Relationship
Barakat, Lydia Yale University School of Medicine None N/A
Campbell, Thomas*
University of Colorado Denver School of Medicine Gilead Sciences Advisory Board, Research Support
Janssen Research Support
Merck Advisory Board
ViiV Advisory Board, Research Support
Healey, Letha HIV/AIDS Bureau Health Resources and Services Administration None N/A
Kitchell, Ellen University of Texas Southwestern None N/A
Robbins, Gregory Massachusetts General Hospital AIDS Clinical Trial Group (ACTG) Research Support
Biogen Equity Interest
Citius Pharmaceuticals Research Support
Emergent Biosolutions Research Support
Gilead Sciences Research Support
Leonard Meron Biosciences Research Support
Pfizer Research Support
United Healthcare Equity Interest
* Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from January 1, 2019, through January 1, 2020

Download Guidelines